Thu. 29 Feb 2024, 7:31am ET
Benzinga
Earnings, Earnings Misses, News
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.30) by 20 percent. The company reported quarterly sales of $33.75 million which missed the analyst consensus estimate of $35.40 million by 4.68 percent. This is a 0.50 percent increase over sales of $33.58 million the same period last year.